Delbert G. Robinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Delbert G. Robinson has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- John M. Kane
Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, USA
6 shared publications Majnu John
Department of Psychiatry, Division of Research, The Zucker Hillside Hospital Division of Northwell Health, Glen Oaks, USA
5 shared publicationsNina R. Schooler
SUNY Downstate Medical Center, Department of Psychiatry, Brooklyn, NY, USA
5 shared publicationsPatricia Marcy
Vanguard Research Group , Glen Oaks, NY , USA
3 shared publications- Philipp Homan
Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich and University of Zurich, Zurich, Switzerland
3 shared publications Piper Meyer-Kalos
Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical School , Minneapolis, MN 55454
3 shared publications
Latest Publications
- 20 August 2026
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 52 (5)
Psychiatric Hospitalization Outcomes after Enrollment in Coordinated Specialty Care for First-Episode Psychosis: Findings from the Early Psychosis Intervention Network (EPINET) in the United States
Background: Psychiatric hospitalization is a key outcome in first-episode psychosis (FEP). Coordinated Specialty Care (CSC) is increasingly implemented across the United States, but hospitalization outcomes in real-world CSC settings remain uncertain. Study design: This cohort study used data from the Early Psychosis Intervention Network. The sample included 2951 individuals across six networks (87 clinics in 15 states), assessed at admission and every 6 months for 2 years. Outcomes included psychiatric hospitalization, number of admissions, and total nights hospitalized. Logistic, Poisson, and negative binomial regression models were used. Study results: At admission, 71.2% had been hospitalized in the prior 6 months. Older age was associated with lower hospitalization risk (odds ratios [OR], 0.95; 95% confidence intervals [CI], 0.92–0.98; P < .001), fewer admissions (incidence rate ratios [IRR], 0.98; 95% CI, 0.96–0.99; P = .003), and fewer nights hospitalized (risk ratios [RR], 0.96; 95% CI, 0.94–0.99; P = .002). Prior hospitalization predicted higher risk (OR, 1.52; 95% CI, 1.18–1.98; P = .001), more admissions (IRR, 2.89; 95% CI, 2.49–3.36; P < .001), and more nights hospitalized (RR, 3.04; 95% CI, 2.47–3.71; P < .001). Shorter duration of untreated psychosis (DUP) was associated with more admissions (IRR, 0.93; 95% CI, 0.89–0.96; P < .001) and more nights hospitalized (RR, 0.92; 95% CI, 0.88–0.96; P = .001). Conclusions: Hospitalizations decreased substantially after CSC admission and remained low over 2 years in this large national FEP cohort. Prior hospitalization and markers of earlier illness course (younger age and shorter DUP) were associated with higher hospitalization burden, highlighting targets for CSC care refinement.
- 20 August 2026
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 52 (5)
Psychiatric Hospitalization Outcomes after Enrollment in Coordinated Specialty Care for First-Episode Psychosis: Findings from the Early Psychosis Intervention Network (EPINET) in the United States
Background: Psychiatric hospitalization is a key outcome in first-episode psychosis (FEP). Coordinated Specialty Care (CSC) is increasingly implemented across the United States, but hospitalization outcomes in real-world CSC settings remain uncertain. Study design: This cohort study used data from the Early Psychosis Intervention Network. The sample included 2951 individuals across six networks (87 clinics in 15 states), assessed at admission and every 6 months for 2 years. Outcomes included psychiatric hospitalization, number of admissions, and total nights hospitalized. Logistic, Poisson, and negative binomial regression models were used. Study results: At admission, 71.2% had been hospitalized in the prior 6 months. Older age was associated with lower hospitalization risk (odds ratios [OR], 0.95; 95% confidence intervals [CI], 0.92–0.98; P < .001), fewer admissions (incidence rate ratios [IRR], 0.98; 95% CI, 0.96–0.99; P = .003), and fewer nights hospitalized (risk ratios [RR], 0.96; 95% CI, 0.94–0.99; P = .002). Prior hospitalization predicted higher risk (OR, 1.52; 95% CI, 1.18–1.98; P = .001), more admissions (IRR, 2.89; 95% CI, 2.49–3.36; P < .001), and more nights hospitalized (RR, 3.04; 95% CI, 2.47–3.71; P < .001). Shorter duration of untreated psychosis (DUP) was associated with more admissions (IRR, 0.93; 95% CI, 0.89–0.96; P < .001) and more nights hospitalized (RR, 0.92; 95% CI, 0.88–0.96; P = .001). Conclusions: Hospitalizations decreased substantially after CSC admission and remained low over 2 years in this large national FEP cohort. Prior hospitalization and markers of earlier illness course (younger age and shorter DUP) were associated with higher hospitalization burden, highlighting targets for CSC care refinement.
- 4 April 2025
- Published by Elsevier in Schizophrenia Research
- Vol. 279, 79-86
The problem of missing data for learning health systems focused on first-episode psychosis
- 4 April 2025
- Published by Elsevier in Schizophrenia Research
- Vol. 279, 79-86
The problem of missing data for learning health systems focused on first-episode psychosis
- 10 March 2025
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 51 (6) , 1668-1678
Cerebellar-Cortical Connectivity and Prediction of Antipsychotic Treatment Response in First-Episode Psychosis
Background: The cerebellum has traditionally been associated with motor functions, but recent evidence highlights its critical role in cognitive and emotional regulation, contributing to the neuropathology of schizophrenia. Our previous data-driven research demonstrated that cerebellar-cortical functional connectivity can predict antipsychotic treatment outcomes in first-episode psychosis (FEP). The present study aimed to investigate specific cerebellar functional systems involved in treatment prediction. Study Design: This study included 127 patients with FEP who underwent 12 weeks of antipsychotic monotherapy (either risperidone or aripiprazole). Baseline resting-state functional MRI data were collected from two 3T scanners, and functional connectivity between 10 predefined cerebellar functional systems and the whole brain was analyzed. Psychotic symptom changes were measured using the Brief Psychiatric Rating Scale-Anchored version (BPRS-A). Connectivity patterns were examined in relation to treatment outcomes. Study Results: Higher baseline connectivity between the cerebellar auditory system and cortical regions, including the visual cortex, dorsolateral prefrontal cortex, and the hippocampus, predicted worse treatment outcome. In contrast, stronger connectivity between cerebellar cognitive systems (default mode and frontoparietal networks) and the anterior cingulate cortex (ACC) and medial prefrontal cortex was associated with better treatment outcome. These findings were consistently present in data acquired from both scanners and both drugs. Conclusions: Our results identify specific cerebellar-cortical circuitries as prognostic biomarkers for predicting psychosis treatment outcomes, and suggest that cerebellar auditory and cognitive systems may be potential targets for future interventions aimed at improving treatment efficacy in FEP.
- 10 March 2025
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 51 (6) , 1668-1678
Cerebellar-Cortical Connectivity and Prediction of Antipsychotic Treatment Response in First-Episode Psychosis
Background: The cerebellum has traditionally been associated with motor functions, but recent evidence highlights its critical role in cognitive and emotional regulation, contributing to the neuropathology of schizophrenia. Our previous data-driven research demonstrated that cerebellar-cortical functional connectivity can predict antipsychotic treatment outcomes in first-episode psychosis (FEP). The present study aimed to investigate specific cerebellar functional systems involved in treatment prediction. Study Design: This study included 127 patients with FEP who underwent 12 weeks of antipsychotic monotherapy (either risperidone or aripiprazole). Baseline resting-state functional MRI data were collected from two 3T scanners, and functional connectivity between 10 predefined cerebellar functional systems and the whole brain was analyzed. Psychotic symptom changes were measured using the Brief Psychiatric Rating Scale-Anchored version (BPRS-A). Connectivity patterns were examined in relation to treatment outcomes. Study Results: Higher baseline connectivity between the cerebellar auditory system and cortical regions, including the visual cortex, dorsolateral prefrontal cortex, and the hippocampus, predicted worse treatment outcome. In contrast, stronger connectivity between cerebellar cognitive systems (default mode and frontoparietal networks) and the anterior cingulate cortex (ACC) and medial prefrontal cortex was associated with better treatment outcome. These findings were consistently present in data acquired from both scanners and both drugs. Conclusions: Our results identify specific cerebellar-cortical circuitries as prognostic biomarkers for predicting psychosis treatment outcomes, and suggest that cerebellar auditory and cognitive systems may be potential targets for future interventions aimed at improving treatment efficacy in FEP.
- 20 October 2024
- Published by Elsevier in Schizophrenia Research
- Vol. 274, 307-314
The COMPASS scale for the assessment of individuals with first episode psychotic disorders
- 20 October 2024
- Published by Elsevier in Schizophrenia Research
- Vol. 274, 307-314
The COMPASS scale for the assessment of individuals with first episode psychotic disorders
- Open Access
- 11 March 2023
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (5) , 2249-2264
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Introduction Studies evaluating patient and healthcare professional (HCP) preferences regarding long-acting injectable (LAI) antipsychotic agent attributes are lacking. Methods Surveys were administered to physicians, nurses, and patients who had at least two experiences with TV-46000, an investigational subcutaneous LAI antipsychotic agent for the treatment of schizophrenia, as part of the SHINE study (NCT03893825). Survey topics included preferences for route of administration, potential LAI dosing intervals (once-weekly, twice a month, once a month [q1m], every 2 months [q2m]), injection location, ease of use, syringe type, needle length, and need for reconstitution. Results Patients (n = 63) had a mean (SD) age of 35.6 (9.6) years, age at diagnosis of 18 (10) years, and were mostly male (75%). There were 49 HCPs: 24 physicians and 25 nurses. Patients rated “a short needle” (68%), a “choice of [q1m or q2m] dosing interval” (59%), and “injection instead of oral tablet” (59%) as the most important features. HCPs rated “single injection to initiate treatment” (61%), “flexible dosing interval” (84%), and “injection instead of oral tablet” (59%) as the most important features. Subcutaneous injections were rated “easy to [receive/administer]” by 62% of patients and 84% of HCPs. When choosing between subcutaneous injections and intramuscular injections, 65% of HCPs preferred subcutaneous injections and 57% of patients preferred intramuscular injections. It was important to most HCPs to have four dose strength options (78%), a prefilled syringe (96%), and no need for reconstitution (90%). Conclusions Patients had a range of responses, and on some issues patient and HCP preferences differed. Altogether, this suggests the importance of providing patients with a range of options and the importance of patient–HCP discussions on treatment preference for LAIs.
- 11 March 2023
- Published by Springer Nature in Advances in Therapy
- Vol. 40 (5) , 2249-2264
Open AccessPatient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
Introduction Studies evaluating patient and healthcare professional (HCP) preferences regarding long-acting injectable (LAI) antipsychotic agent attributes are lacking. Methods Surveys were administered to physicians, nurses, and patients who had at least two experiences with TV-46000, an investigational subcutaneous LAI antipsychotic agent for the treatment of schizophrenia, as part of the SHINE study (NCT03893825). Survey topics included preferences for route of administration, potential LAI dosing intervals (once-weekly, twice a month, once a month [q1m], every 2 months [q2m]), injection location, ease of use, syringe type, needle length, and need for reconstitution. Results Patients (n = 63) had a mean (SD) age of 35.6 (9.6) years, age at diagnosis of 18 (10) years, and were mostly male (75%). There were 49 HCPs: 24 physicians and 25 nurses. Patients rated “a short needle” (68%), a “choice of [q1m or q2m] dosing interval” (59%), and “injection instead of oral tablet” (59%) as the most important features. HCPs rated “single injection to initiate treatment” (61%), “flexible dosing interval” (84%), and “injection instead of oral tablet” (59%) as the most important features. Subcutaneous injections were rated “easy to [receive/administer]” by 62% of patients and 84% of HCPs. When choosing between subcutaneous injections and intramuscular injections, 65% of HCPs preferred subcutaneous injections and 57% of patients preferred intramuscular injections. It was important to most HCPs to have four dose strength options (78%), a prefilled syringe (96%), and no need for reconstitution (90%). Conclusions Patients had a range of responses, and on some issues patient and HCP preferences differed. Altogether, this suggests the importance of providing patients with a range of options and the importance of patient–HCP discussions on treatment preference for LAIs.
- 5 October 2022
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 47 (13) , 2245-2251
Frontal lobe fALFF measured from resting-state fMRI as a prognostic biomarker in first-episode psychosis
Clinical response to antipsychotic drug treatment is highly variable, yet prognostic biomarkers are lacking. The goal of the present study was to test whether the fractional amplitude of low-frequency fluctuations (fALFF), as measured from baseline resting-state fMRI data, can serve as a potential biomarker of treatment response to antipsychotics. Patients in the first episode of psychosis (n = 126) were enrolled in two prospective studies employing second-generation antipsychotics (risperidone or aripiprazole). Patients were scanned at the initiation of treatment on a 3T MRI scanner (Study 1, GE Signa HDx, n = 74; Study 2, Siemens Prisma, n = 52). Voxelwise fALFF derived from baseline resting-state fMRI scans served as the primary measure of interest, providing a hypothesis-free (as opposed to region-of-interest) search for regions of the brain that might be predictive of response. At baseline, patients who would later meet strict criteria for clinical response (defined as two consecutive ratings of much or very much improved on the CGI, as well as a rating of ≤3 on psychosis-related items of the BPRS-A) demonstrated significantly greater baseline fALFF in bilateral orbitofrontal cortex compared to non-responders. Thus, spontaneous activity in orbitofrontal cortex may serve as a prognostic biomarker of antipsychotic treatment.
- 5 October 2022
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 47 (13) , 2245-2251
Frontal lobe fALFF measured from resting-state fMRI as a prognostic biomarker in first-episode psychosis
Clinical response to antipsychotic drug treatment is highly variable, yet prognostic biomarkers are lacking. The goal of the present study was to test whether the fractional amplitude of low-frequency fluctuations (fALFF), as measured from baseline resting-state fMRI data, can serve as a potential biomarker of treatment response to antipsychotics. Patients in the first episode of psychosis (n = 126) were enrolled in two prospective studies employing second-generation antipsychotics (risperidone or aripiprazole). Patients were scanned at the initiation of treatment on a 3T MRI scanner (Study 1, GE Signa HDx, n = 74; Study 2, Siemens Prisma, n = 52). Voxelwise fALFF derived from baseline resting-state fMRI scans served as the primary measure of interest, providing a hypothesis-free (as opposed to region-of-interest) search for regions of the brain that might be predictive of response. At baseline, patients who would later meet strict criteria for clinical response (defined as two consecutive ratings of much or very much improved on the CGI, as well as a rating of ≤3 on psychosis-related items of the BPRS-A) demonstrated significantly greater baseline fALFF in bilateral orbitofrontal cortex compared to non-responders. Thus, spontaneous activity in orbitofrontal cortex may serve as a prognostic biomarker of antipsychotic treatment.
- 11 June 2022
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 48 (5) , 1021-1031
Outcomes During and After Early Intervention Services for First-Episode Psychosis: Results Over 5 Years From the RAISE-ETP Site-Randomized Trial
To examine long-term effects of early intervention services (EIS) for first-episode psychosis, we compared Heinrichs-Carpenter Quality of Life (QLS) and Positive and Negative Syndrome Scale (PANSS) scores and inpatient hospitalization days over 5 years with data from the site-randomized RAISE-ETP trial that compared the EIS NAVIGATE (17 sites; 223 participants) and community care (CC) (17 sites; 181 participants). Inclusion criteria were: age 15–40 years; DSM-IV diagnoses of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder not otherwise specified; first psychotic episode; antipsychotic medication taken for ≤6 months. NAVIGATE-randomized participants could receive NAVIGATE from their study entry date until NAVIGATE ended when the last-enrolled NAVIGATE participant completed 2 years of treatment. Assessments occurred every 6 months. 61% of participants had assessments conducted ≥2 years; 31% at 5 years. Median follow-up length was CC 30 months and NAVIGATE 38 months. Primary analyses assumed data were not-missing-at-random (NMAR); sensitivity analyses assumed data were missing-at-random (MAR). MAR analyses found no significant treatment-by-time interactions for QLS or PANSS. NMAR analyses revealed that NAVIGATE was associated with a 13.14 (95%CI:6.92,19.37) unit QLS and 7.73 (95%CI:2.98,12.47) unit PANSS better improvement and 2.53 (95%CI:0.59,4.47) fewer inpatient days than CC (all comparisons significant). QLS and PANSS effect sizes were 0.856 and 0.70. NAVIGATE opportunity length (mean 33.8 (SD = 5.1) months) was not associated (P = .72) with QLS outcome; duration of untreated psychosis did not moderate (P = .32) differential QLS outcome. While conclusions are limited by the low rate of five-year follow-up, the data support long-term benefit of NAVIGATE compared to community care.
- 11 June 2022
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 48 (5) , 1021-1031
Outcomes During and After Early Intervention Services for First-Episode Psychosis: Results Over 5 Years From the RAISE-ETP Site-Randomized Trial
To examine long-term effects of early intervention services (EIS) for first-episode psychosis, we compared Heinrichs-Carpenter Quality of Life (QLS) and Positive and Negative Syndrome Scale (PANSS) scores and inpatient hospitalization days over 5 years with data from the site-randomized RAISE-ETP trial that compared the EIS NAVIGATE (17 sites; 223 participants) and community care (CC) (17 sites; 181 participants). Inclusion criteria were: age 15–40 years; DSM-IV diagnoses of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder not otherwise specified; first psychotic episode; antipsychotic medication taken for ≤6 months. NAVIGATE-randomized participants could receive NAVIGATE from their study entry date until NAVIGATE ended when the last-enrolled NAVIGATE participant completed 2 years of treatment. Assessments occurred every 6 months. 61% of participants had assessments conducted ≥2 years; 31% at 5 years. Median follow-up length was CC 30 months and NAVIGATE 38 months. Primary analyses assumed data were not-missing-at-random (NMAR); sensitivity analyses assumed data were missing-at-random (MAR). MAR analyses found no significant treatment-by-time interactions for QLS or PANSS. NMAR analyses revealed that NAVIGATE was associated with a 13.14 (95%CI:6.92,19.37) unit QLS and 7.73 (95%CI:2.98,12.47) unit PANSS better improvement and 2.53 (95%CI:0.59,4.47) fewer inpatient days than CC (all comparisons significant). QLS and PANSS effect sizes were 0.856 and 0.70. NAVIGATE opportunity length (mean 33.8 (SD = 5.1) months) was not associated (P = .72) with QLS outcome; duration of untreated psychosis did not moderate (P = .32) differential QLS outcome. While conclusions are limited by the low rate of five-year follow-up, the data support long-term benefit of NAVIGATE compared to community care.
- 30 May 2022
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 53 (9) , 4114-4120
Relapse prevention through health technology program reduces hospitalization in schizophrenia
Background: Psychiatric hospitalization is a major driver of cost in the treatment of schizophrenia. Here, we asked whether a technology-enhanced approach to relapse prevention could reduce days spent in a hospital after discharge.Methods: The Improving Care and Reducing Cost (ICRC) study was a quasi-experimental clinical trial in outpatients with schizophrenia conducted between 26 February 2013 and 17 April 2015 at 10 different sites in the USA in an outpatient setting. Patients were between 18 and 60 years old with a diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified. Patients received usual care or a technology-enhanced relapse prevention program during a 6-month period after discharge. The health technology program included in-person, individualized relapse prevention planning with treatments delivered via smartphones and computers, as well as a web-based prescriber decision support program. The main outcome measure was days spent in a psychiatric hospital during 6 months after discharge.Results: The study included 462 patients, of which 438 had complete baseline data and were thus used for propensity matching and analysis. Control participants (N = 89; 37 females) were enrolled first and received usual care for relapse prevention followed by 349 participants (128 females) who received technology-enhanced relapse prevention. During 6-month follow-up, 43% of control and 24% of intervention participants were hospitalized (χ2 = 11.76, pb = −4.58, 95% CI −9.03 to −0.13, p = 0.044) in the intervention condition compared to control.Conclusions: These results suggest that technology-enhanced relapse prevention is an effective and feasible way to reduce rehospitalization days among patients with schizophrenia.
- 30 May 2022
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 53 (9) , 4114-4120
Relapse prevention through health technology program reduces hospitalization in schizophrenia
Background: Psychiatric hospitalization is a major driver of cost in the treatment of schizophrenia. Here, we asked whether a technology-enhanced approach to relapse prevention could reduce days spent in a hospital after discharge.Methods: The Improving Care and Reducing Cost (ICRC) study was a quasi-experimental clinical trial in outpatients with schizophrenia conducted between 26 February 2013 and 17 April 2015 at 10 different sites in the USA in an outpatient setting. Patients were between 18 and 60 years old with a diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified. Patients received usual care or a technology-enhanced relapse prevention program during a 6-month period after discharge. The health technology program included in-person, individualized relapse prevention planning with treatments delivered via smartphones and computers, as well as a web-based prescriber decision support program. The main outcome measure was days spent in a psychiatric hospital during 6 months after discharge.Results: The study included 462 patients, of which 438 had complete baseline data and were thus used for propensity matching and analysis. Control participants (N = 89; 37 females) were enrolled first and received usual care for relapse prevention followed by 349 participants (128 females) who received technology-enhanced relapse prevention. During 6-month follow-up, 43% of control and 24% of intervention participants were hospitalized (χ2 = 11.76, pb = −4.58, 95% CI −9.03 to −0.13, p = 0.044) in the intervention condition compared to control.Conclusions: These results suggest that technology-enhanced relapse prevention is an effective and feasible way to reduce rehospitalization days among patients with schizophrenia.
- Open Access
- 1 January 2020
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin Open
- Vol. 1 (1) , sgaa014
Interaction of Cannabis Use Disorder and Striatal Connectivity in Antipsychotic Treatment Response
Antipsychotic (AP) medications are the mainstay for the treatment of schizophrenia spectrum disorders (SSD), but their efficacy is unpredictable and widely variable. Substantial efforts have been made to identify prognostic biomarkers that can be used to guide optimal prescription strategies for individual patients. Striatal regions involved in salience and reward processing are disrupted as a result of both SSD and cannabis use, and research demonstrates that striatal circuitry may be integral to response to AP drugs. In the present study, we used functional magnetic resonance imaging (fMRI) to investigate the relationship between a history of cannabis use disorder (CUD) and a striatal connectivity index (SCI), a previously developed neural biomarker for AP treatment response in SSD. Patients were part of a 12-week randomized, double-blind controlled treatment study of AP drugs. A sample of 48 first-episode SSD patients with no more than 2 weeks of lifetime exposure to AP medications, underwent a resting-state fMRI scan pretreatment. Treatment response was defined a priori as a binary (response/nonresponse) variable, and a SCI was calculated in each patient. We examined whether there was an interaction between lifetime CUD history and the SCI in relation to treatment response. We found that CUD history moderated the relationship between SCI and treatment response, such that it had little predictive value in SSD patients with a CUD history. In sum, our findings highlight that biomarker development can be critically impacted by patient behaviors that influence neurobiology, such as a history of CUD.
- 1 January 2020
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin Open
- Vol. 1 (1) , sgaa014
Open AccessInteraction of Cannabis Use Disorder and Striatal Connectivity in Antipsychotic Treatment Response
Antipsychotic (AP) medications are the mainstay for the treatment of schizophrenia spectrum disorders (SSD), but their efficacy is unpredictable and widely variable. Substantial efforts have been made to identify prognostic biomarkers that can be used to guide optimal prescription strategies for individual patients. Striatal regions involved in salience and reward processing are disrupted as a result of both SSD and cannabis use, and research demonstrates that striatal circuitry may be integral to response to AP drugs. In the present study, we used functional magnetic resonance imaging (fMRI) to investigate the relationship between a history of cannabis use disorder (CUD) and a striatal connectivity index (SCI), a previously developed neural biomarker for AP treatment response in SSD. Patients were part of a 12-week randomized, double-blind controlled treatment study of AP drugs. A sample of 48 first-episode SSD patients with no more than 2 weeks of lifetime exposure to AP medications, underwent a resting-state fMRI scan pretreatment. Treatment response was defined a priori as a binary (response/nonresponse) variable, and a SCI was calculated in each patient. We examined whether there was an interaction between lifetime CUD history and the SCI in relation to treatment response. We found that CUD history moderated the relationship between SCI and treatment response, such that it had little predictive value in SSD patients with a CUD history. In sum, our findings highlight that biomarker development can be critically impacted by patient behaviors that influence neurobiology, such as a history of CUD.
- Open Access
Relapse prevention through health technology program reduces hospitalization in schizophrenia
Importance: Psychiatric hospitalization is a major driver of cost in the treatment of schizophrenia. Symptom relapses are a frequent cause of hospitalization and both are primary source of burden to patients and their supporters. Objective: To determine whether a novel, multicomponent, and technology-enhanced approach to relapse prevention in outpatients following a psychiatric hospitalization could reduce days spent in a hospital after discharge. Design: The Improving Care and Reducing Cost (ICRC) study was a quasi-experimental clinical trial in outpatients with schizophrenia conducted between February 2013 and April 2015 at 10 different sites in the US. Data were obtained from 89 participants who received usual relapse prevention services, followed by a second cohort of 349 participants who received the technology-enhanced relapse prevention program. Both groups were followed for 6 months. Setting: Outpatient setting. Participants: Patients were between 18 and 60 years old; had a diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified; and were currently hospitalized or had been hospitalized within the past 30 days. Intervention: Patients received usual care or a technology-enhanced relapse prevention program during a 6-month period after discharge. Main Outcome(s) and Measure(s): Days spent in a psychiatric hospital during 6 months after discharge. Results: The study included 438 patients. Control participants ( N = 89; 37 females) were enrolled first and received usual care for relapse prevention, and followed by 349 participants (128 females) who received technology-enhanced relapse prevention. Days of hospitalization were reduced by 4 days (Mean days: b = −4.25, 95% CI: −8.29; −0.21, P = 0.039) during follow-up in the intervention condition compared to control. Conclusions and Relevance: The reduction in days spent in the hospital for participants in the technology-informed relapse prevention program compared to those who received usual care, and the previously reported high satisfaction and usability suggest that technology-enhanced relapse prevention is an effective and feasible way to reduce rehospitalization days among patients with schizophrenia. Key points: Question: Can rehospitalizations in schizophrenia be prevented at reduced cost by innovative mobile technology-delivered interventions? Findings: In this clinical trial with 438 patients, a technology-enhanced relapse prevention program compared to usual services reduced an average of four days of hospitalization per patient during the first 6 months following an index hospitalization. Meaning: Relapse prevention through a health technology may improve care while reducing costs associated with hospitalization.
Open AccessRelapse prevention through health technology program reduces hospitalization in schizophrenia
Importance: Psychiatric hospitalization is a major driver of cost in the treatment of schizophrenia. Symptom relapses are a frequent cause of hospitalization and both are primary source of burden to patients and their supporters. Objective: To determine whether a novel, multicomponent, and technology-enhanced approach to relapse prevention in outpatients following a psychiatric hospitalization could reduce days spent in a hospital after discharge. Design: The Improving Care and Reducing Cost (ICRC) study was a quasi-experimental clinical trial in outpatients with schizophrenia conducted between February 2013 and April 2015 at 10 different sites in the US. Data were obtained from 89 participants who received usual relapse prevention services, followed by a second cohort of 349 participants who received the technology-enhanced relapse prevention program. Both groups were followed for 6 months. Setting: Outpatient setting. Participants: Patients were between 18 and 60 years old; had a diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise specified; and were currently hospitalized or had been hospitalized within the past 30 days. Intervention: Patients received usual care or a technology-enhanced relapse prevention program during a 6-month period after discharge. Main Outcome(s) and Measure(s): Days spent in a psychiatric hospital during 6 months after discharge. Results: The study included 438 patients. Control participants ( N = 89; 37 females) were enrolled first and received usual care for relapse prevention, and followed by 349 participants (128 females) who received technology-enhanced relapse prevention. Days of hospitalization were reduced by 4 days (Mean days: b = −4.25, 95% CI: −8.29; −0.21, P = 0.039) during follow-up in the intervention condition compared to control. Conclusions and Relevance: The reduction in days spent in the hospital for participants in the technology-informed relapse prevention program compared to those who received usual care, and the previously reported high satisfaction and usability suggest that technology-enhanced relapse prevention is an effective and feasible way to reduce rehospitalization days among patients with schizophrenia. Key points: Question: Can rehospitalizations in schizophrenia be prevented at reduced cost by innovative mobile technology-delivered interventions? Findings: In this clinical trial with 438 patients, a technology-enhanced relapse prevention program compared to usual services reduced an average of four days of hospitalization per patient during the first 6 months following an index hospitalization. Meaning: Relapse prevention through a health technology may improve care while reducing costs associated with hospitalization.